Long‐term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo EGFR T790M: a case report and literature review

Osimertinib is a potent and irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively acts on both EGFR‐sensitive and EGFR T790M‐resistant mutations. Patients with pre‐treatment EGFR T790M mutations (de novo EGFR T790M) respond poorly to existing EGFR‐TKIs...

Descripción completa

Detalles Bibliográficos
Autores principales: Sumi, Toshiyuki, Kamada, Koki, Shijubou, Naoki, Yamada, Yuichi, Nakata, Hisashi, Mori, Yuji, Chiba, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094050/
https://www.ncbi.nlm.nih.gov/pubmed/33976888
http://dx.doi.org/10.1002/rcr2.759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094050/
https://www.ncbi.nlm.nih.gov/pubmed/33976888
http://dx.doi.org/10.1002/rcr2.759

Ejemplares similares